Attached files
| file | filename |
|---|---|
| EX-32 - EXHIBIT 32 - CTI BIOPHARMA CORP | a2019exhibit32sect906certc.htm |
| EX-31.2 - EXHIBIT 31.2 - CTI BIOPHARMA CORP | a2019exhibit312sect302cert.htm |
| EX-31.1 - EXHIBIT 31.1 - CTI BIOPHARMA CORP | a2019exhibit311sect302cert.htm |
| EX-21.1 - EXHIBIT 21.1 - CTI BIOPHARMA CORP | a2019exhibit211subsidiaries.htm |
| EX-10.46 - EXHIBIT 10.46 - CTI BIOPHARMA CORP | a2019exhibit1046directorco.htm |
| EX-4.6 - EXHIBIT 4.6 - CTI BIOPHARMA CORP | a2019exhibit46descriptiono.htm |
| 10-K - 10-K - CTI BIOPHARMA CORP | cti10k12312019document.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) | Form S-3 No. 333-221382 of CTI BioPharma Corp. and the related prospectus |
(2) | Form S-3 No. 333-200453 of CTI BioPharma Corp. and the related prospectus |
(3) | Form S-3 No. 333-192749 of Cell Therapeutics, Inc. and the related prospectus |
(4) | Form S-3 No. 333-192748 of Cell Therapeutics, Inc. and the related prospectus |
(5) | Form S-3 No. 333-182330 of Cell Therapeutics, Inc. and the related prospectus |
(6) | Form S-3 No. 333-163479 of Cell Therapeutics, Inc. and the related prospectus |
(7) | Form S-3 No. 333-157376 of Cell Therapeutics, Inc. and the related prospectus |
(8) | Form S-3 No. 333-152171 of Cell Therapeutics, Inc. and the related prospectus |
(9) | Form S-3 No. 333-149981 of Cell Therapeutics, Inc. and the related prospectus |
(10) | Form S-3 No. 333-149980 of Cell Therapeutics, Inc. and the related prospectus |
(11) | Form S-3 No. 333-134126 of Cell Therapeutics, Inc. and the related prospectus |
(12) | Form S-3 No. 333-108926 of Cell Therapeutics, Inc. and the related prospectus |
(13) | Form S-8 No. 333-231708 pertaining to the CTI BioPharma Corp. Amended and Restated 2017 Equity Incentive Plan |
(14) | Form S-8 No. 333-225116 pertaining to the CTI BioPharma Corp. Amended and Restated 2017 Equity Incentive Plan |
(15) | Form S-8 No. 333-218947 pertaining to the CTI BioPharma Corp. 2017 Equity Incentive Plan |
(16) | Form S-8 No. 333-218946 pertaining to the CTI BioPharma Corp. Stock Option Agreement |
(17) | Form S-8 No. 333-211006 pertaining to the CTI BioPharma Corp. 2015 Equity Incentive Plan, as amended and restated, and the CTI BioPharma Corp. 2017 Equity Incentive Plan |
(18) | Form S-8 No. 333-207177 pertaining to the CTI BioPharma Corp 2007 Employee Stock Purchase Plan, as amended and restated |
(19) | Form S-8 No. 333-207176 pertaining to the CTI BioPharma Corp. 2015 Equity Incentive Plan, as amended and restated, and the CTI BioPharma Corp. 2017 Equity Incentive Plan |
(20) | Form S-8 No. 333-196510 pertaining to the CTI BioPharma Corp. 2007 Equity Incentive Plan, as amended and restated, CTI BioPharma Corp. 2017 Equity Incentive Plan |
(21) | Form S-8 No. 333-189611 pertaining to the Cell Therapeutics, Inc. 2007 Equity Incentive Plan |
(22) | Form S-8 No. 333-184004 pertaining to the Cell Therapeutics, Inc. 2007 Equity Incentive Plan |
(23) | Form S-8 No. 333-178158 pertaining to the Cell Therapeutics, Inc. 2007 Equity Incentive Plan |
(24) | Form S-8 No. 333-170044 pertaining to the Cell Therapeutics, Inc. 2007 Equity Incentive Plan |
(25) | Form S-8 No. 333-162955 pertaining to the Cell Therapeutics, Inc. 2007 Equity Incentive Plan and 2007 Employee Stock Purchase Plan |
(26) | Form S-8 No. 333-158260 pertaining to the Cell Therapeutics, Inc. 2007 Equity Incentive Plan and 2007 Employee Stock Purchase Plan |
(27) | Form S-8 No. 333-152168 pertaining to the Cell Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan |
(28) | Form S-8 No. 333-146624 pertaining to the Cell Therapeutics, Inc. Amended and Restated 2007 Equity Incentive Plan and 2007 Employee Stock Purchase Plan |
of our reports dated March 12, 2020, with respect to the consolidated financial statements of CTI BioPharma Corp. included in this Annual Report (Form 10-K) of CTI BioPharma Corp. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Seattle, Washington
March 12, 2020